PRIA Logo™
117-hr-8586117th Congress

EFFECTIVE Act

Sponsored By: Representative Trone, David J. [D-MD-6]

Unknown

Summary

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug upon a determination that the drug does not provide a significant advantage or clinical superiority compared to other drugs.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Trone, David J. [D-MD-6]

MD • D

Cosponsors

  • Rep. Meuser, Daniel [R-PA-9]

    PA • R

    Sponsored 7/28/2022

  • Rep. Kuster, Ann M. [D-NH-2]

    NH • D

    Sponsored 8/12/2022

  • Rep. Pappas, Chris [D-NH-1]

    NH • D

    Sponsored 9/13/2022

  • Rep. Ruppersberger, C. A. Dutch [D-MD-2]

    MD • D

    Sponsored 9/19/2022

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation